Related references
Note: Only part of the references are listed.Acquired resistance to cancer immunotherapy: Role of tumor-mediated immunosuppression
Reem Saleh et al.
SEMINARS IN CANCER BIOLOGY (2020)
Resistance to Checkpoint Inhibition in Cancer Immunotherapy
Luisa Barrueto et al.
TRANSLATIONAL ONCOLOGY (2020)
Combining Immune Checkpoint Inhibitors with Anti-Angiogenic Agents
Paola Ciciola et al.
JOURNAL OF CLINICAL MEDICINE (2020)
Mechanisms of the Antitumor Activity of Low Molecular Weight Heparins in Pancreatic Adenocarcinomas
Alexandros Bokas et al.
CANCERS (2020)
Tumor-Associated Macrophages: Recent Insights and Therapies
Jiawei Zhou et al.
FRONTIERS IN ONCOLOGY (2020)
Evaluating the Polarization of Tumor-Associated Macrophages Into M1 and M2 Phenotypes in Human Cancer Tissue: Technicalities and Challenges in Routine Clinical Practice
Sharmilla Devi Jayasingam et al.
FRONTIERS IN ONCOLOGY (2020)
Pancreatic ductal adenocarcinoma: Treatment hurdles, tumor microenvironment and immunotherapy
Panagiotis Sarantis et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2020)
Microbiome and cancer immunotherapy
Shanmuga Reddy Chilakapati et al.
CURRENT OPINION IN BIOTECHNOLOGY (2020)
Regulatory T Cells in Tumor Microenvironment and Approach for Anticancer Immunotherapy
Jung-Ho Kim et al.
IMMUNE NETWORK (2020)
PD-1/ PD-L1 blockade as a novel treatment for colorectal cancer
Neda Yaghoubi et al.
BIOMEDICINE & PHARMACOTHERAPY (2019)
Autophagy in endothelial cells and tumor angiogenesis
Marco B. Schaaf et al.
CELL DEATH AND DIFFERENTIATION (2019)
Third-Line Nivolumab Monotherapy in Recurrent SCLC: CheckMate 032
Neal Ready et al.
JOURNAL OF THORACIC ONCOLOGY (2019)
Targeting DNA Methylation and EZH2 Activity to Overcome Melanoma Resistance to Immunotherapy
Abdullah Al Emran et al.
TRENDS IN IMMUNOLOGY (2019)
Patients Selection for Immunotherapy in Solid Tumors: Overcome the Naive Vision of a Single Biomarker
Diego Signorelli et al.
BIOMED RESEARCH INTERNATIONAL (2019)
The Interplay of Autophagy and Tumor Microenvironment in Colorectal Cancer-Ways of Enhancing Immunotherapy Action
Evangelos Koustas et al.
CANCERS (2019)
Complementing the Cancer-Immunity Cycle
Ruben Pio et al.
FRONTIERS IN IMMUNOLOGY (2019)
Recent Advances in Lung Cancer Immunotherapy: Input of T-Cell Epitopes Associated With Impaired Peptide Processing
Marine Leclerc et al.
FRONTIERS IN IMMUNOLOGY (2019)
A Review of the Role of Wnt in Cancer Immunomodulation
Whitney N. Goldsberry et al.
CANCERS (2019)
MicroRNAs, T-cell immunity and immunotherapy
Bikash R. Giri et al.
FUTURE MEDICINAL CHEMISTRY (2019)
Nivolumab plus Ipilimumab in Advanced Non-Small-Cell Lung Cancer
M. D. Hellmann et al.
NEW ENGLAND JOURNAL OF MEDICINE (2019)
Mutation-Derived Neoantigens for Cancer Immunotherapy
John C. Castle et al.
FRONTIERS IN IMMUNOLOGY (2019)
Autophagy-related Proteins as a Prognostic Factor of Patients With Colorectal Cancer
Evangelos Koustas et al.
AMERICAN JOURNAL OF CLINICAL ONCOLOGY-CANCER CLINICAL TRIALS (2019)
Nivolumab plus ipilimumab versus sunitinib in first-line treatment for advanced renal cell carcinoma: extended follow-up of efficacy and safety results from a randomised, controlled, phase 3 trial
Robert Motzer et al.
LANCET ONCOLOGY (2019)
Role of miRNAs in immune responses and immunotherapy in cancer
Maria Angelica Cortez et al.
GENES CHROMOSOMES & CANCER (2019)
The multifaceted role of autophagy in cancer and the microenvironment
Hendrik Folkerts et al.
MEDICINAL RESEARCH REVIEWS (2019)
Effective chemoimmunotherapy by co-delivery of doxorubicin and immune adjuvants in biodegradable nanoparticles
Candido G. Da Silva et al.
THERANOSTICS (2019)
Cancer Immune Checkpoint Inhibitor Therapy and the Gut Microbiota
Arthur E. Frankel et al.
INTEGRATIVE CANCER THERAPIES (2019)
Estimation of the Percentage of US Patients With Cancer Who Are Eligible for and Respond to Checkpoint Inhibitor Immunotherapy Drugs
Alyson Haslam et al.
JAMA NETWORK OPEN (2019)
Drug resistance in cancer immunotherapy: new strategies to improve checkpoint inhibitor therapies
Jesus Rodriguez-Pascual et al.
CANCER DRUG RESISTANCE (2019)
Molecular Mechanisms and Countermeasures of Immunotherapy Resistance in Malignant Tumor
Xiaoyue Jiang et al.
JOURNAL OF CANCER (2019)
Gut microbiome modulates response to anti-PD-1 immunotherapy in melanoma patients
V. Gopalakrishnan et al.
SCIENCE (2018)
The Influence of the Gut Microbiome on Cancer, Immunity, and Cancer Immunotherapy
Vancheswaran Gopalakrishnan et al.
CANCER CELL (2018)
Mechanisms of Resistance to PD-1 and PD-L1 Blockade
Theodore S. Nowicki et al.
CANCER JOURNAL (2018)
Autophagy in dendritic cells
Ghita Ghislat et al.
CELLULAR & MOLECULAR IMMUNOLOGY (2018)
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Haneen Shalabi et al.
HAEMATOLOGICA (2018)
Atezolizumab versus chemotherapy in patients with platinum-treated locally advanced or metastatic urothelial carcinoma (IMvigor211): a multicentre, open-label, phase 3 randomised controlled trial
Thomas Powles et al.
LANCET (2018)
Autophagy and MHC-restricted antigen presentation
Jan Valecka et al.
MOLECULAR IMMUNOLOGY (2018)
Improving immunotherapy outcomes with anti-angiogenic treatments and vice versa
Kabir A. Khan et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2018)
Atezolizumab for First-Line Treatment of Metastatic Nonsquamous NSCLC
M. A. Socinski et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
The commensal microbiome is associated with anti-PD-1 efficacy in metastatic melanoma patients
Vyara Matson et al.
SCIENCE (2018)
The gut microbiota and immune checkpoint inhibitors
Audrey Humphries et al.
HUMAN VACCINES & IMMUNOTHERAPEUTICS (2018)
Sequential loss of tumor surface antigens following chimeric antigen receptor T-cell therapies in diffuse large B-cell lymphoma
Haneen Shalabi et al.
HAEMATOLOGICA (2018)
Melanoma response to anti-PD-L1 immunotherapy requires JAK1 signaling, but not JAK2
Na Luo et al.
ONCOIMMUNOLOGY (2018)
Radiation therapy and PD-1/PD-L1 blockade: the clinical development of an evolving anticancer combination
Jun Gong et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2018)
Anti-PD-1 and Anti-CTLA-4 Therapies in Cancer: Mechanisms of Action, efficacy, and Limitations
Judith A. Seidel et al.
FRONTIERS IN ONCOLOGY (2018)
Roles of the immune system in cancer: from tumor initiation to metastatic progression
Hugo Gonzalez et al.
GENES & DEVELOPMENT (2018)
The Roles of Autophagy in Cancer
Chul Won Yun et al.
INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES (2018)
The role of autophagy in the treatment of BRAF mutant colorectal carcinomas differs based on microsatellite instability status
Evangelos Koustas et al.
PLOS ONE (2018)
Upgraded role of autophagy in colorectal carcinomas
Evangelos Koustas et al.
WORLD JOURNAL OF GASTROINTESTINAL ONCOLOGY (2018)
Immunotherapy and pancreatic cancer: unique challenges and potential opportunities
Kate Young et al.
THERAPEUTIC ADVANCES IN MEDICAL ONCOLOGY (2018)
Suppression of Type I IFN Signaling in Tumors Mediates Resistance to Anti-PD-1 Treatment That Can Be Overcome by Radiotherapy
Xiaohong Wang et al.
CANCER RESEARCH (2017)
Regulatory T cells in cancer immunotherapy
Atsushi Tanaka et al.
CELL RESEARCH (2017)
nab-Paclitaxel as a potential partner with checkpoint inhibitors in solid tumors
Hatem H. Soliman
ONCOTARGETS AND THERAPY (2017)
Primary Resistance to PD-1 Blockade Mediated by JAK1/2 Mutations
Daniel Sanghoon Shin et al.
CANCER DISCOVERY (2017)
Translation reprogramming is an evolutionarily conserved driver of phenotypic plasticity and therapeutic resistance in melanoma
Paola Falletta et al.
GENES & DEVELOPMENT (2017)
Loss of PTEN Is Associated with Resistance to Anti-PD-1 Checkpoint Blockade Therapy in Metastatic Uterine Leiomyosarcoma
Suzanne George et al.
IMMUNITY (2017)
Human regulatory B cells in health and disease: therapeutic potential
Claudia Mauri et al.
JOURNAL OF CLINICAL INVESTIGATION (2017)
Impact of antibiotics on outcome in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors.
Lisa Derosa et al.
JOURNAL OF CLINICAL ONCOLOGY (2017)
The crosstalk between autophagic and endo-/exosomal pathways in antigen processing for MHC presentation in anticancer T cell immune responses
Liangshun You et al.
JOURNAL OF HEMATOLOGY & ONCOLOGY (2017)
Resistance to checkpoint blockade therapy through inactivation of antigen presentation
Moshe Sade-Feldman et al.
NATURE COMMUNICATIONS (2017)
Epi-drugs in combination with immunotherapy: a new avenue to improve anticancer efficacy
Roberta Mazzone et al.
CLINICAL EPIGENETICS (2017)
Cancer immunotherapy: Historical Perspective of a Clinical Revolution and emerging Preclinical Animal Models
William K. Decker et al.
FRONTIERS IN IMMUNOLOGY (2017)
Co-targeting of EGFR and autophagy signaling is an emerging treatment strategy in metastatic colorectal cancer
Evangelos Koustas et al.
CANCER LETTERS (2017)
Baseline gut microbiota predicts clinical response and colitis in metastatic melanoma patients treated with ipilimumab
N. Chaput et al.
ANNALS OF ONCOLOGY (2017)
Primary, Adaptive, and Acquired Resistance to Cancer Immunotherapy
Padmanee Sharma et al.
CELL (2017)
The Tumor Antigen NY-ESO-1 Mediates Direct Recognition of Melanoma Cells by CD4(+) T Cells after Intercellular Antigen Transfer
Jean Francois Fonteneau et al.
JOURNAL OF IMMUNOLOGY (2016)
Resistance Mechanisms to Immune-Checkpoint Blockade in Cancer: Tumor-Intrinsic and -Extrinsic Factors
Jonathan M. Pitt et al.
IMMUNITY (2016)
Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
Roy S. Herbst et al.
LANCET (2016)
Pembrolizumab versus Chemotherapy for PD-L1-Positive Non-Small-Cell Lung Cancer
Martin Reck et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Mutations Associated with Acquired Resistance to PD-1 Blockade in Melanoma
Jesse M. Zaretsky et al.
NEW ENGLAND JOURNAL OF MEDICINE (2016)
Autophagy Beyond Intracellular MHC Class II Antigen Presentation
Christian Muenz
TRENDS IN IMMUNOLOGY (2016)
Immunotherapy and Oncogenic Pathways: The PTEN Connection
Naiyer A. Rizvi et al.
CANCER DISCOVERY (2016)
Tumor CTLA-4 overexpression predicts poor survival in patients with nasopharyngeal carcinoma
Pei-Yu Huang et al.
ONCOTARGET (2016)
Tumor-released autophagosomes induce IL-10-producing B cells with suppressive activity on T lymphocytes via TLR2-MyD88-NF-κB signal pathway
Meng Zhou et al.
ONCOIMMUNOLOGY (2016)
Glimpse into the future: harnessing autophagy to promote anti-tumor immunity with the DRibbles vaccine
David B. Page et al.
JOURNAL FOR IMMUNOTHERAPY OF CANCER (2016)
Relationship of VEGF/VEGFR with immune and cancer cells: staggering or forward?
Yu -Ling Li et al.
CANCER BIOLOGY & MEDICINE (2016)
Acquired resistance to immunotherapy and future challenges
Nicholas P. Restifo et al.
NATURE REVIEWS CANCER (2016)
Differential use of autophagy by primary dendritic cells specialized in cross-presentation
Justine D. Mintern et al.
AUTOPHAGY (2015)
Inhibition of autophagy by 3-MA enhances IL-24-induced apoptosis in human oral squamous cell carcinoma cells
Jichen Li et al.
JOURNAL OF EXPERIMENTAL & CLINICAL CANCER RESEARCH (2015)
Mast cells as targets for immunotherapy of solid tumors
Sharon A. Oldford et al.
MOLECULAR IMMUNOLOGY (2015)
Epigenetic silencing of TH1-type chemokines shapes tumour immunity and immunotherapy
Dongjun Peng et al.
NATURE (2015)
Melanoma-intrinsic β-catenin signalling prevents anti-tumour immunity
Stefani Spranger et al.
NATURE (2015)
Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer
H. Borghaei et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Combined Nivolumab and Ipilimumab or Monotherapy in Untreated Melanoma
J. Larkin et al.
NEW ENGLAND JOURNAL OF MEDICINE (2015)
Commensal Bifidobacterium promotes antitumor immunity and facilitates anti-PD-L1 efficacy
Ayelet Sivan et al.
SCIENCE (2015)
Genomic correlates of response to CTLA-4 blockade in metastatic melanoma
Eliezer M. Van Allen et al.
SCIENCE (2015)
Macrophages and cancer: from mechanisms to therapeutic implications
Renato Ostuni et al.
TRENDS IN IMMUNOLOGY (2015)
Macroautophagy in endogenous processing of self- and pathogen-derived antigens for MHC class II presentation
Fernanda V. Duraes et al.
FRONTIERS IN IMMUNOLOGY (2015)
Augmenting antitumor immune responses with epigenetic modifying agents
Erika Heninger et al.
FRONTIERS IN IMMUNOLOGY (2015)
Immune Escape Mechanisms as a Guide for Cancer Immunotherapy
Gregory L. Beatty et al.
CLINICAL CANCER RESEARCH (2015)
Autophagy in T-cell development, activation and differentiation
Alisha W. Bronietzki et al.
IMMUNOLOGY AND CELL BIOLOGY (2015)
Modified Vaccinia Virus Ankara-Infected Dendritic Cells Present CD4+ T-Cell Epitopes by Endogenous Major Histocompatibility Complex Class II Presentation Pathways
Frank Thiele et al.
JOURNAL OF VIROLOGY (2015)
Immune cell promotion of metastasis
Takanori Kitamura et al.
NATURE REVIEWS IMMUNOLOGY (2015)
PD-1 blockade induces responses by inhibiting adaptive immune resistance
Paul C. Tumeh et al.
NATURE (2014)
Eradication of metastatic mouse cancers resistant to immune checkpoint blockade by suppression of myeloid-derived cells
KiBem Kim et al.
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA (2014)
Autophagy is a critical regulator of memory CD8+ T cell formation
Daniel J. Puleston et al.
ELIFE (2014)
Impaired Autophagy, Defective T Cell Homeostasis, and a Wasting Syndrome in Mice with a T Cell-Specific Deletion of Vps34
Vrajesh V. Parekh et al.
JOURNAL OF IMMUNOLOGY (2013)
Mutational heterogeneity in cancer and the search for new cancer-associated genes
Michael S. Lawrence et al.
NATURE (2013)
Blocking the interleukin 2 (IL2)-induced systemic autophagic syndrome promotes profound antitumor effects and limits toxicity
Michael T. Lotze et al.
AUTOPHAGY (2012)
Evaluation of CTLA-4 expression and relevance as a novel prognostic factor in patients with non-small cell lung cancer
Sandra Salvi et al.
CANCER IMMUNOLOGY IMMUNOTHERAPY (2012)
Inhibiting Systemic Autophagy during Interleukin 2 Immunotherapy Promotes Long-term Tumor Regression
Xiaoyan Liang et al.
CANCER RESEARCH (2012)
Foxp3 Exploits a Pre-Existent Enhancer Landscape for Regulatory T Cell Lineage Specification
Robert M. Samstein et al.
CELL (2012)
Interleukin-10 produced by B cells is crucial for the suppression of Th17/Th1 responses, induction of T regulatory type 1 cells and reduction of collagen-induced arthritis
Natalie A. Carter et al.
ARTHRITIS RESEARCH & THERAPY (2012)
Intersection of autophagy with pathways of antigen presentation
Natalie L. Patterson et al.
PROTEIN & CELL (2012)
Regulation of T cell homeostasis and responses by Pten
Ryan H. Newton et al.
FRONTIERS IN IMMUNOLOGY (2012)
B10 cells and regulatory B cells balance immune responses during inflammation, autoimmunity, and cancer
David J. DiLillo et al.
YEAR IN IMMUNOLOGY 2 (2010)
Association between Faecalibacterium prausnitzii and dietary fibre in colonic fermentation in healthy human subjects
Robin F. J. Benus et al.
BRITISH JOURNAL OF NUTRITION (2010)
Autophagy and the Integrated Stress Response
Guido Kroemer et al.
MOLECULAR CELL (2010)
Activated monocytes in peritumoral stroma of hepatocellular carcinoma foster immune privilege and disease progression through PD-L1
Dong-Ming Kuang et al.
JOURNAL OF EXPERIMENTAL MEDICINE (2009)
Autophagy and its Role in MHC-Mediated Antigen Presentation
Victoria L. Crotzer et al.
JOURNAL OF IMMUNOLOGY (2009)
Different regulation of MHC Class I antigen processing components in human tumors
Barbara Seliger
JOURNAL OF IMMUNOTOXICOLOGY (2008)
The tumor microenvironment and its role in promoting tumor growth
T. L. Whiteside
ONCOGENE (2008)
Share Paper
